Search research articles
Contact Us
Filters
Showing results (61-70 of 67) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 67 results.
Cancer Medicine
|
August 29, 2023
MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B-cell lymphoma patients
Yanjie Wang, Donglin Liu, Xudong Zhang, et al.
Frontiers in Immunology
|
February 27, 2026
Characterizing tumor microenvironment heterogeneity in EBV<sup>+</sup> nTNKL vs ENKTL using spatial transcriptomics and MIF
Siyu Qian, Zeyuan Wang, Yue Zhang, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
September 14, 2021
Long non-coding RNA SLC2A1-AS1 induced by GLI3 promotes aerobic glycolysis and progression in esophageal squamous cell carcinoma by sponging miR-378a-3p to enhance Glut1 expression
Hongtao Liu, Qing Zhang, Yinsen Song, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
May 1, 2026
NTRK Fusion Landscape in 195 Positive Cases of 17 Tumors: A Chinese Multicenter Retrospective Study with Optimized Pan-TRK IHC Screening
Shafei Wu, Jian Wang, Wentao Yang, et al.
The Lancet. Gastroenterology & Hepatology
|
January 9, 2022
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
Xiangrui Meng, Tao Wu, Yonggui Hong, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
October 16, 2025
Cytological Classification Diagnosis for Thyroid Nodules via Multimodal Model Deep Learning
Yuanzheng Lou, Yongjian Su, Haoda Lu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 22, 2024
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study
Xiangrui Meng, Junsheng Wang, Jin Xia, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 67) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 67 results.
Cancer Medicine
|
August 29, 2023
MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B-cell lymphoma patients
Yanjie Wang, Donglin Liu, Xudong Zhang, et al.
Frontiers in Immunology
|
February 27, 2026
Characterizing tumor microenvironment heterogeneity in EBV<sup>+</sup> nTNKL vs ENKTL using spatial transcriptomics and MIF
Siyu Qian, Zeyuan Wang, Yue Zhang, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
September 14, 2021
Long non-coding RNA SLC2A1-AS1 induced by GLI3 promotes aerobic glycolysis and progression in esophageal squamous cell carcinoma by sponging miR-378a-3p to enhance Glut1 expression
Hongtao Liu, Qing Zhang, Yinsen Song, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
May 1, 2026
NTRK Fusion Landscape in 195 Positive Cases of 17 Tumors: A Chinese Multicenter Retrospective Study with Optimized Pan-TRK IHC Screening
Shafei Wu, Jian Wang, Wentao Yang, et al.
The Lancet. Gastroenterology & Hepatology
|
January 9, 2022
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
Xiangrui Meng, Tao Wu, Yonggui Hong, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
October 16, 2025
Cytological Classification Diagnosis for Thyroid Nodules via Multimodal Model Deep Learning
Yuanzheng Lou, Yongjian Su, Haoda Lu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 22, 2024
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study
Xiangrui Meng, Junsheng Wang, Jin Xia, et al.
Page
of 7